We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
In the latest trading session, Medpace (MEDP - Free Report) closed at $624.20, marking a +1.94% move from the previous day. The stock's change was more than the S&P 500's daily gain of 1.49%. At the same time, the Dow added 0.71%, and the tech-heavy Nasdaq gained 2.26%.
The provider of outsourced clinical development services's shares have seen a decrease of 1.36% over the last month, not keeping up with the Medical sector's loss of 1.14% and the S&P 500's gain of 0.1%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company's earnings per share (EPS) are projected to be $4.45, reflecting a 15.28% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $708.75 million, up 7.4% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $17.54 per share and a revenue of $2.84 billion, representing changes of +14.79% and +12.38%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Medpace possesses a Zacks Rank of #3 (Hold).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 34.91. Its industry sports an average Forward P/E of 17.31, so one might conclude that Medpace is trading at a premium comparatively.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.73. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services industry currently had an average PEG ratio of 1.48 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 104, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
In the latest trading session, Medpace (MEDP - Free Report) closed at $624.20, marking a +1.94% move from the previous day. The stock's change was more than the S&P 500's daily gain of 1.49%. At the same time, the Dow added 0.71%, and the tech-heavy Nasdaq gained 2.26%.
The provider of outsourced clinical development services's shares have seen a decrease of 1.36% over the last month, not keeping up with the Medical sector's loss of 1.14% and the S&P 500's gain of 0.1%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company's earnings per share (EPS) are projected to be $4.45, reflecting a 15.28% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $708.75 million, up 7.4% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $17.54 per share and a revenue of $2.84 billion, representing changes of +14.79% and +12.38%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Medpace possesses a Zacks Rank of #3 (Hold).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 34.91. Its industry sports an average Forward P/E of 17.31, so one might conclude that Medpace is trading at a premium comparatively.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.73. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services industry currently had an average PEG ratio of 1.48 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 104, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.